Post-neoadjuvant treatment pancreatic cancer resectability and outcome prediction using CT, 18F-FDG PET/MRI and CA 19–9

Table 4 Predictive factors for recurrence-free survival in patients who underwent R0 resection

Characteristic	Univariate			Multivariate
Characteristic	Hazard ratio	95% CI	p-value	Hazard ratio	95% CI	p-value
Gender (male)	0.46	0.21–1.00	0.049	0.55	0.23–1.31	0.178
Age (per 1 year)	1.02	0.97–1.07	0.472
Baseline CT resectability category according to multidisciplinary team conference	0.49	0.24–1.00	0.051
Post-NAT CT resectability category according to three reviewers in consensus	0.63	0.26–1.52	0.289
Increased uptake at tumor-vessel contact on post-NAT PET of PET/MRI	2.99	1.36–6.55	0.011	4.37	1.13–16.92	0.033
ADC value < 1.40 × 10^–3 mm²/s at tumor-vessel contact	1.20	0.56–2.58	0.632
T stage^a	1.53	1.06–2.22	0.024	1.48	0.87–2.52	0.152
N stage^a	2.16	1.08–4.32	0.034	1.04	0.42–2.55	0.936
Lymphatic invasion^a	4.08	1.64–10.17	0.006	1.94	0.64–5.85	0.239
Vascular invasion^a	2.97	1.38–6.39	0.008	5.36	1.73–16.59	0.004
Perineural invasion^a	2.72	1.15–6.43	0.015	1.16	0.29–4.64	0.836
Tumor grade^a	1.59	1.00–2.52	0.048	1.28	0.72–2.30	0.402
Tumor regression grade^ab	1.57	1.01–2.43	0.037	0.49	0.21–1.17	0.107
CA 19–9 response	2.00	0.75–5.34	0.139

CI Confidence interval, NAT Neoadjuvant therapy, PET Positron emission tomography, ADC Apparent diffusion coefficient, CA 19–9 Carbohydrate antigen 19–9
^aPathologically confirmed
^bThe College of American Pathologists grading systems

ISSN: 1470-7330